Click here for slides on this topic


VADT

Abbreviation for the Vetarans Affair Diabetes Trial, which investigated the impact of intensive and standard glucose control on cardiovascular events among military veterans who had a suboptimal response to antihyperglycemic therapy.
The following content matched the glossary term: VADT

AHA ADA prevention of CVD in T2D - Hypoglycemia & CVD

Top

Summary of evidence for hypoglycemia & cardiovascular disease (CVD) from the AHA ADA CVD prevention in type 2 diabetes guidelines.

NDEI.org Expert Commentary Vivian Fonseca MD on Results of ELIXA the First Cardiovascular Safety Study to Report Outcomes With A GLP-1 Receptor Agonist

Top

In this diabetes expert blog, Vivian Fonseca, MD, provides insights on results of the ELIXA cardiovascular safety study of the novel (at time of publishing) GLP-1 receptor agonist, lixisenatide.

Fonseca commentary on ADVANCE, SOS, VADT

Top

Expert commentary from NDEI Education Council Member Vivian A. Fonseca, MD, on data from post-hoc analyses of ADVANCE, SOS, and VADT.

Clinical Insights in Diabetes Newsletter December 2012

Top

Clinical Insights® in Diabetes newsletter December 2012 

Once-weekly exenatide vs once-daily liraglutide in DURATION-6, HDL-C and microvascular risk in ADVANCE, statins and valvular calcification in VADT, bariatric surgery and cardiovascular events in obesity and type 2 diabetes in SOS. 

Progression of vascular calcification is increased with statin use in the Veterans Affairs Diabetes Trial (VADT).

Top

Exclusive! Expert commentary webcast from Vivian Fonseca, MD, on this post-hoc analysis of VADT. Saremi A, Bahn G, Reaven PD; for the VADT Investigators. Progression of vascular calcification is increased with statin use in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care. 2012;35:2390-2392. Cross-sectional data from the Veterans Affairs Diabetes Trial (VADT) showed that participants with coronary artery or abdominal aortic calcification had an increased prevalence of cardiovascular disease, including peripheral artery disease and coronary artery disease.

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 11, 2012

Top

Daily coverage of American Diabetes Association 72nd Scientific Sessions  June 11, 2012

ORIGIN trial results, insulin and cancer, TINSAL-T2D results, and more.

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 8, 2012

Top

Daily coverage of American Diabetes Association 72nd Scientific Sessions  June 8, 2012

Diabetes and hypoglycemia, clinical management of diabetes, obesity treatment, diabetes in long-term care, and more. 

Glycemic Control: How Low Should You Go?

Top

Glycemic Control: How Low Should You Go? NDEI Education Council Co-Chair Burton E. Sobel, MD, provides expert commentary on the debate over intensive versus somewhat less intensive glycemic control in the context of a recent study by Zhao et al assessing the impact of hypoglycemia associated with antihyperglycemic medications on vascular risk in type 2 diabetes

Pharmacist-led shared medical appointments for multiple cardiovascular risk reduction in patients with type 2 diabetes

Top

Cohen LB, Taviera TH, Khatana SA, Dooley AG, Pirraglia PA, Wu WC. Pharmacist-led shared medical appointments for multiple cardiovascular risk reduction in patients with type 2 diabetes. Diabetes Educ. 2011 Oct 21. [Epub ahead of print]. To assess whether VA MEDIC-E (Veterans Affairs Multi-disciplinary Education and Diabetes Intervention for Cardiac risk reduction— Extended for 6 months), a pharmacist-led shared medical appointments program, could improve attainment of target goals for hypertension, hyperglycemia, hyperlipidemia, and tobacco use in patients with type 2 diabetes compared to standard primary care after 6 months of intervention.

Glucose control and vascular complications in veterans with type 2 diabetes

Top

Duckworth W, Abraira C, Moritz T, et al; for the VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-139. The effects of intensive glucose control on cardiovascular events in patients with long-standing type 2 diabetes mellitus remain uncertain.

1 2 Next 

Slide Library Results

Search Results for: VADT Slides Found: 21
VADT: Comparing Intensive With Standard Glucose Therapy, Primary Outcome
VADT: Comparing Intensive With Standard Glucose Therapy, Secondary Outcomes
VADT: Comparing Intensive With Standard Glucose Therapy, Change in Median A1C
VADT: Comparing Intensive With Standard Glucose Therapy, Adverse Events
Type 2 Diabetes Therapy and Cardiovascular Events: Comparing VADT With Other Trials
Meta-Analysis: Intensive vs Standard Glucose Treatment on A1C Concentration at Follow-Up
Meta-Analysis: Intensive vs Standard Glucose Treatment on Non-Fatal Myocardial Infarc
Meta-Analysis: Intensive vs Standard Glucose Treatment on CHD
Meta-Analysis: Conclusion
VADT: Primary Endpoint
VADT: Effect of BMI on Rates of Severe Hypoglycemia
ADVANCE Post-hoc Analysis: Low HDL-C and Microvascular Event Risk
ADVANCE Post-hoc Analysis: HDL-C Predicts Microvascular Risk
VADT Post-hoc Analysis: Statin Use and Artery Calcification
VADT Post-hoc Analysis: Satin Use and CAC Progression
SOS Post-hoc Analysis: Effect of Bariatric Surgery on CV Events
SOS Post-hoc Analysis: Total CV Events in Obese Subjects with Type 2 Diabetes
SOS Post-hoc Analysis: MI in Obese Subjects with Type 2 Diabetes
SOS Post-hoc Analysis: Stroke in Obese Subjects with Type 2 Diabetes
Individualized Diabetes Therapy for CVD Prevention in Type 2 Diabetes AHA ADA | NDEI
Hypoglycemia & CVD Risk Type 2 Diabetes AHA ACC Guidelines PPT | NDEI